Results 71 to 80 of about 102,854 (205)

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer [PDF]

, 2019
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease.
Belardinilli, Francesca, Bellavia, Diana, Bonfiglio, Caterina, Canettieri, Gianluca, Capalbo, Carlo, Cardinali, Beatrice, Colella, Mariarosaria, Colicchia, Valeria, Coppa, Anna, Cortesi, Enrico, Filetti, Marco, Giannini, Giuseppe, Infante, Paola, Longo, Flavia, Magri, Valentina, Malapelle, Umberto, Marchetti, Paolo, Mezi, Silvia, Milanetti, Edoardo, Nicolussi, Arianna, Paci, Paola, Pecorari, Silvia, Petroni, Marialaura, Pisapia, Pasquale, Prete, Alessandra, Raimondo, Domenico, Santoni, Matteo, Tessitore, Alessandra, Troncone, Giancarlo, Valentini, Virginia   +29 more
core   +2 more sources

EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]

, 2018
A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico, Gazzaniga, Paola, Raimondi, Cristina, Urbano, Federica   +3 more
core   +1 more source

Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas

Veterinary Sciences, 2019
The presence of BRAF variant V595E, as well as an increased cyclooxygenase-2 (COX-2) expression in canine transitional cell carcinoma (TCC) are well-described in the literature.
Julia M. Grassinger, Sophie Merz, Heike Aupperle-Lellbach, Hanna Erhard, Robert Klopfleisch   +4 more
doaj   +1 more source

BRAF Mutation Heterogeneity in Melanoma Lesions

Acta Dermato Venereologica, 2019
Abstract is missing (Short communication)
Kaori Sakaizawa, Atsuko Ashida, Yukiko Kiniwa, Ryuhei Okuyama   +3 more
openaire   +4 more sources

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations [PDF]

New England Journal of Medicine, 2012
Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.In this open-label study ...
Flaherty, Keith T, Infante, Jeffery R, Daud, Adil, Gonzalez, Rene, Kefford, Richard F, Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A, Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V, Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B, Patel, Kiran, Weber, Jeffrey   +25 more
openaire   +4 more sources

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China

Diagnostic Pathology, 2019
Background To determine the relevance of the single or combination mutations of BRAF V600E, TERT, and NRAS genes and the clinicopathologic relationship in papillary thyroid cancer (PTC).
Meiling Huang, Changjiao Yan, Jingjing Xiao, Ting Wang, Rui Ling   +4 more
doaj   +1 more source

Oncogenic Activation of MAP Kinase by BRAF Pseudogene in Thyroid Tumors

Neoplasia: An International Journal for Oncology Research, 2009
Activating BRAF mutations have been reported in 40% of papillary thyroid carcinomas (PTCs). The involvement of BRAF pseudogene in thyroid tumorigenesis has not previously been studied.
Minjing Zou, Essa Y. Baitei, Ali S. Alzahrani, Futwan Al-Mohanna, Nadir R. Farid, Brian Meyer, Yufei Shi   +6 more
doaj   +1 more source

BRAF V600E and lymph node metastases in papillary thyroid cancer

Endocrine Connections, 2020
Objective: To evaluate the relationship between the BRAF V600E mutation in lymph node metastasis (LNM) and its invasive characteristics in papillary thyroid cancer (PTC).
Pan Chen, Liqin Pan, Wensi Huang, Huijuan Feng, Wei Ouyang, Juqing Wu, Jing Wang, Yuying Deng, Jiaxin Luo, Yanying Chen   +9 more
doaj   +1 more source

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. [PDF]

, 2017
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. However, it remains unclear whether and how genomic heterogeneity is constrained during tumor evolution.
Bivona, Trever G, Cai, Mei-Chun, Chen, Hong-Zhuan, Chen, Minjiang, Fu, Yujie, Gao, Wei-Qiang, Gu, Zhenyu, Jing, Ying, Ma, Pengfei, Shen, Ying, Wang, Mengzhao, Wu, Jie, Yan, Ying, Zhang, Shengzhe, Zhao, Xiaojing, Zhu, Liang, Zhuang, Guanglei   +16 more
core   +2 more sources

BRAFMutations in Conjunctival Melanoma

Investigative Opthalmology & Visual Science, 2004
An activating mutation in exon 15 of the BRAF gene has been found in a high proportion of cutaneous melanomas and cutaneous nevi but not in uveal melanoma. Conjunctival melanoma shows greater clinical similarity to cutaneous melanoma than does uveal melanoma. The purpose of this study was to determine whether the T1799A BRAF mutation found in cutaneous
Heather, Gear, Hawys, Williams, Ewan G, Kemp, Fiona, Roberts   +3 more
openaire   +2 more sources